Table 1.
Baseline characteristics of intervention group and control group
| Characteristics | Control group | Intervention group | P value |
|---|---|---|---|
| N=51 | N=51 | ||
| Age (Mean [SD], years) | 40.5 [9.2] | 41.3 [8.8] | 0.580a |
| Men - % (n) | 66.7 (34) | 66.7 (34) | 1.000b |
| Ethnicity - % (n) | 0.830b | ||
| Caucasian | 70.6 (36) | 68.6 (35) | |
| Black/ african descent | 29.4 (15) | 31.4 (16) | |
|
HIV Diagnosis
(Mean [SD], years) |
7.5 [5.6] | 8.3 [6.4] | 0.690a |
| HIV Treatment Duration (Mean [SD], years) | 5.7 [4.2] | 6.5 [5.5] | 0.780a |
| Number of tablets/day (Mean [SD]) | 9.3 [4.4] | 10.1 [4.2] | 0.250a |
| ART changes during the first 4 weeks of the study - % (n) | 9.8 (5) | 7.8 (4) | 1.000c |
| CD4 + (Mean [SD], cells/mm 3 ) | 304.0 [277.1] | 310.4 [302.0] | 0.980a |
| CD4 + >200 cells/mm3 % (n) | 56.9 (29) | 54.9 (28) | 0.840b |
| CD4 + >350 cells/mm3 % (n) | 31.4 (16) | 33.3 (17) | 0.830b |
| CD4 + >500 cells/mm3 % (n) | 15.7 (8) | 17.7 (9) | 0.800b |
| Viral load <50 copies/ml % (n) | 60.8 (31) | 64.8 (33) | 0.190b |
|
Number of Comorbidities
(Mean [SD]) |
2.5 [1.6] | 2.8 [2.1] | 0.730a |
| Type of comorbidities % (n) | |||
| Hepatitis C | 23.5 (12) | 21.6 (11) | 0.630b |
| Tobaccoism | 15.8 (8) | 11.8 (6) | 0.570b |
| Neurotoxoplasmosis | 9.8 (5) | 9.8 (5) | 0.510b |
| Hypertriglyceridemia | 3.9 (2) | 9.8 (5) | 0.440c |
| Pulmonary tuberculosis | 13.7 (7) | 3.9 (2) | 0.160c |
| ART regimen % (n) | 0.800b | ||
| TDF+3TC+EFV | 17.6 (9) | 21.6 (11) | |
| AZT+3TC+EFV | 15.7 (8) | 21.6 (11) | |
| AZT+3TC+LPV/r | 9.8 (5) | 7.8 (4) | |
| TDF+3TC+LPV/r | 11.8 (6) | 11.8 (6) | |
| Others | 45.1 (23) | 37.2 (19) | |
| Substance abuse % (n) | 0.418b | ||
| Alcohol | 19.6 (10) | 29.4 (15) | |
| Tobacco | 27.4 (14) | 33.3 (17) | |
| Illicit drugs | 13.73 (7) | 7.8 (4) |
Note: aMann-Whitney test; bChi-square test;cFisher’s exact test.
Abbreviations: ART, antiretroviral therapy; AZT, zidovudine; CD4+, lymphocyte T CD4+; EFV, efavirenz; LPV/r, lopinavir/ritonavir; n, absolute number of patients; SD, standard deviation; TDF, tenofovir; 3TC, lamivudine.